Experimental kidney drug DF-003 enters first human safety trial

NCT ID NCT05997641

Ongoing Knowledge-focused Sponsor: Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety and metabolism of an experimental oral drug called DF-003 in 96 healthy volunteers. The drug aims to reduce inflammation and kidney scarring, potentially offering a new treatment for chronic kidney disease. Participants receive either a single or multiple doses of DF-003 or a placebo, and are closely monitored for side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DF-003 (an experimental oral drug that targets inflammation and fibrosis)
What this could lead to: If successful, this could pave the way for a new treatment for chronic kidney disease by reducing inflammation and kidney scarring.
What could go wrong: This is a very early Phase 1 trial in healthy people, so it only tests safety and how the drug is processed. It does not yet test if it works for kidney disease, and many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SAFETY, AND TOLERABILITY

Contacts and locations

Locations

Altasciences Clinical Los Angeles, Inc

Cypress, California, 90630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.